rimonabant

Subscribe to Selected New Research on rimonabant

478 relevant articles (60 outcomes, 113 trials/studies) found for this Bio-Agent

Description: a potent & selective antagonist of the brain cannabinoid receptor; structure given in first source

Also Known As:

Acomplia; N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride; SR 141716; SR 141716A; SR-141716A; SR141716; SR141716A; Sanofi-Synthelabo brand of rimonabant; Zimulti

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 25

1-Ring Heterocyclic Compounds

Experts

1.	Després, Jean-Pierre: 5 articles (04/2008 - 11/2005)
2.	Pi-Sunyer, Xavier: 3 articles (02/2008 - 02/2008)
3.	Van Gaal, Luc: 3 articles (02/2008 - 02/2008)
4.	Scheen, André: 3 articles (02/2008 - 02/2008)
5.	Van Gaal, Luc F: 3 articles (06/2007 - 04/2005)
6.	Scheen, André J: 3 articles (06/2007 - 04/2005)
7.	Doggrell, Sheila A: 2 articles (10/2008 - 10/2005)
8.	Cannon, Christopher P: 2 articles (04/2008 - 03/2006)
9.	Christensen, Robin: 2 articles (12/2007 - 11/2007)
10.	Kristensen, Pernelle Kruse: 2 articles (12/2007 - 11/2007)

Related Diseases

1.	Obesity 04/01/2008 - "However, given the efficacy of this treatment and the magnitude of the obesity problem, rimonabant may prove to be a valuable adjunct in targeting obesity-related cardiovascular risk factors." 04/01/2005 - "In humans, rimonabant appears to be effective for treatment of obesity and smoking cessation. " 05/01/2007 - "Is rimonabant a safe and effective treatment for obesity?" 06/01/2004 - "Rimonabant was shown to be safe and effective in treating the combined cardiovascular risk factors of smoking and obesity. " 08/27/2008 - "Ongoing studies aim at further demonstrating the potential of rimonabant in the management of type 2 diabetes, in the prevention of type 2 diabetes and in the protection against cardiovascular complications in (diabetic) patients with abdominal obesity." Order ALL the reference details at left...
2.	Weight Loss (Weight Reduction) 07/01/2008 - "Weight loss from baseline to 2 years in the intention-to-treat population was significantly greater with rimonabant 20 mg (mean +/- SD: -5.5 +/- 7.7 kg; P < 0.001) and 5 mg (-2.9 +/- 6.5 kg; P = 0.002) than placebo (-1.2 +/- 6.8 kg). " 11/11/2006 - "Weight loss was significantly greater after 1 year in both rimonabant groups than in the placebo group (placebo: -1.4 kg [SD 3.6]; 5 mg/day: -2.3 kg [4.2], p=0.01 vs placebo; 20 mg/day: -5.3 kg [5.2], p<0.0001 vs placebo). " 01/01/2006 - "A significantly greater proportion of rimonabant than placebo recipients achieved the clinically significant weight-loss target of > or =5% or > or =10% of initial weight. " 04/16/2005 - "FINDINGS: Weight loss at 1 year was significantly greater in patients treated with rimonabant 5 mg (mean -3.4 kg [SD 5.7]; p=0.002 vs placebo) and 20 mg (-6.6 kg [7.2]; p<0.001 vs placebo) compared with placebo (-1.8 kg [6.4]). " 07/01/2006 - "Is rimonabant a safe and effective therapy for sustained weight loss and improved cardiometabolic risk factors?" Order ALL the reference details at left...
3.	Insulin Resistance 01/16/2009 - "Interestingly, the rimonabant-treated adipo(-/-)ob/ob mice also exhibited significant amelioration of insulin resistance, although the degree of improvement was significantly lower as compared with that in the ob/ob mice. " 07/01/2008 - "Rimonabant is shown in the current issue of British Journal of Pharmacology to attenuate weight gain in Zucker rats, an experimental model of insulin resistance. " 01/16/2009 - "Significant improvement of insulin resistance was observed in the ob/ob mice following rimonabant treatment, associated with significant up-regulation of the plasma adiponectin levels, in particular, of high molecular weight adiponectin. " 12/01/2008 - "RESULTS: After 12 weeks of rimonabant there was a significant reduction (mean +/- SEM) in weight (104.6 +/- 4.6 vs. 98.4 +/- 4.7 kg, P < 0.01), waist circumference (116.0 +/- 3.3 vs. 109.2 +/- 3.7 cm, P < 0.01), hip circumference (128.5 +/- 4.0 vs. 124.1 +/- 4.2 cm, P < 0.03), waist-hip ratio (0.90 +/- 0.02 vs. 0.88 +/- 0.01, P < 0.01) free androgen index (FAI) (26.6 +/- 6.1 vs. 16.6 +/- 4.1, P < 0.01), testosterone [4.6 +/- 0.4 vs. 3.1 +/- 0.3 nmol/l (132.7 +/- 11.5 vs. 89.4 +/- 8.65 ng/dl), P < 0.01] and insulin resistance as measured by the homeostasis model assessment (HOMA) method (4.4 +/- 0.5 vs. 3.4 +/- 0.4, P = 0.05). " 01/01/2009 - "This study was undertaken to determine if subsequent metformin treatment after rimonabant would maintain the improvement in weight, insulin resistance and hyperandrogenaemia in PCOS. " Order ALL the reference details at left...
4.	Syndrome 02/01/2009 - "Rimonabant: a rapidly expanding role in the management of metabolic and systemic disorders besides polycystic ovarian syndrome." 07/01/2008 - "Rimonabant in rats with a metabolic syndrome: good news after the depression." 05/01/2007 - "Rimonabant may be a useful adjunct to lifestyle and behavior modification in the treatment of obese subjects with metabolic syndrome or multiple cardiometabolic risk factors." 03/01/2007 - "The frequency of metabolic syndrome also decreased significantly with rimonabant 20 mg daily. " 08/01/2006 - "[Rimonabant--a panacea for patients with metabolic syndrome?]" Order ALL the reference details at left...
5.	Body Weight (Weight, Body) 08/01/2009 - "Rimonabant treatment transiently reduced food intake, while inducing body weight loss throughout the study. " 05/01/2008 - "Clinical trials investigating rimonabant treatment resulted in substantial reductions in body weight and markers for cardiometabolic risk in study participants. " 12/17/2007 - "(Recently, an FDA Advisory Committee recommended a delay in the approval of rimonabant because of safety issues that need to be addressed in further studies.) Compared with placebo, rimonabant 20 mg significantly decreased body weight and waist circumference measurements. " 06/01/2007 - "Preclinical studies have shown that rimonabant, the first CB1-receptor blocker to be available in clinical practice, could not only induce a reduction in food intake, but could also produce body weight loss beyond what could be explained by its effect on food intake. " 06/01/2006 - "Although tolerance developed to the anorectic effect of rimonabant, total food intake was significantly decreased over the 14-day study period and fully accounted for the observed reductions in body weight. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	CB1 Cannabinoid Receptor (CB1 Receptor)
2.	Triglycerides (Triacylglycerol)
3.	HDL Cholesterol
4.	Endocannabinoids (Endocannabinoid)
5.	Glucose (Dextrose)
6.	rimonabant
7.	Cholesterol
8.	Lipids
9.	Cannabinoid Receptors (Cannabinoid Receptor)
10.	Adiponectin

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Self Administration (Administration, Self)
3.	Ganglionectomy
4.	Vagotomy
5.	Analgesia

Best Treatments:
Research Summary Report
on Obesity

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 882 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>